Please login to the form below

Not currently logged in
Email:
Password:

Spinraza

This page shows the latest Spinraza news and features for those working in and with pharma, biotech and healthcare.

Orphan drugs dominate UK Prix Galien shortlist, medtech debuts

Orphan drugs dominate UK Prix Galien shortlist, medtech debuts

Seven companies have been shortlisted for the Orphan Product Award; Amicus (Galafold), Biogen (Spinraza), Biomarin (Brineura), Eusa (Qarziba), Intercept (Ocaliva), Kyowa Kirin (Crysvita) and Shire (Revestive).

Latest news

  • Novartis buys gene therapy firm AveXis for $8.7bn Novartis buys gene therapy firm AveXis for $8.7bn

    Its antisense drug Spinraza (nusinersen) is being sold in the US for $750, 000 in the first year and $375, 000 thereafter and is predicted to become a $1bn-$2bn product

  • AZ adds another Ionis drug in $330m kidney disease deal AZ adds another Ionis drug in $330m kidney disease deal

    After many years at the forefront of efforts to develop antisense drugs, Ionis’pipeline has started to deliver with Biogen-partnered Spinraza (nusinersen) on the market for spinal muscular atrophy and

  • Biogen cuts $217m deal for Karyopharm neurology drug Biogen cuts $217m deal for Karyopharm neurology drug

    licensed to Roche, as well as spinal muscular atrophy therapy Spinraza (nusinersen). ... Spinraza - licensed from Ionis - brought in a whopping $363m for Biogen in the quarter, ahead of analyst expectations, thanks to its $750, 000 first-year price

  • NICE finally starts review of Biogen’s Spinraza for SMA NICE finally starts review of Biogen’s Spinraza for SMA

    NICE finally starts review of Biogen’ s Spinraza for SMA. Will evaluate the treatment based on its Single Technology Appraisal process. ... However, it adds: “there is concern that this route is not set up to assess rare disease drugs, like

  • Biogen wins European spinal muscular atrophy first Biogen wins European spinal muscular atrophy first

    Biogen wins European spinal muscular atrophy first. Spinraza wins accelerated approval to treat patients with the most common form of SMA. ... Biogen now has approval in Europe to go with its US license for Spinraza, its drug for the genetic disease

More from news
Approximately 7 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • No incentive for a cure No incentive for a cure

    to 12-week course. And Spinraza from Biogen, the first ever disease-modifying treatment for spinal muscular atrophy (SMA), which increases the body’s ability to produce SMN protein critical to. ... And the lack of affordability - as well as the bad

  • The good, the bad and the ugly The good, the bad and the ugly

    Tecfidera (MS) and Spinraza (Spinal Muscular Atrophy) are expected to generate big sales, while Tysabril (MS and Crohn’s Disease) and Avonex (MS) are expected to see sales drop due to

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    2015 and in the EU 2016) and Spinraza (for the treatment of spinal muscular atrophy, only approved in the US).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
WCG

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics